| Compound |
Receptor selectivity |
Indication or use (phase) |
| Agonists |
|
|
| Adenosine (Adenocard, Adenoscan) |
A1, A2A |
Paroxysmal supraventricular tachycardia (approved), myocardial perfusion imaging (approved), other uses in testing |
| Apadenoson |
A2A |
Myocardial perfusion imaging (III) |
| Regadenoson |
A2A |
Myocardial perfusion imaging (completed) |
| BAY 60-6583 |
A2B |
Atherosclerosis (preclinical) |
| Binodenoson |
A2A |
Myocardial perfusion imaging (III) |
| BVT.115959 |
A2A |
Diabetic neuropathic pain (II) |
| Capadenoson |
A1 |
Atrial fibrillation, chronic treatment (II) |
| LASSBio-1027 |
A2A/A3 |
Systemic hypertension (preclinical) |
| LASSBio-1386 |
A2A |
Pulmonary hypertension (preclinical) |
| LASSBio-1359 |
A2A |
Pulmonary hypertension (preclinical) |
| LASSBio-1366 |
A2A |
Pulmonary hypertension (preclinical) |
| MRS3558 |
A3 |
Autoimmune inflammatory diseases (preclinical) |
| Cl-IB-MECA |
A3 |
Liver cancer (I-II) |
| CP608,039 |
A3 |
Cardiac ischemia (discontinued) |
| Antagonists |
|
|
| Caffeine |
A1/A2A/A2B/A3 |
Motor manifestations of Parkinson’s disease and excessive daytime somnolence in Parkinson’s disease (completed) |
| ATL 844 |
A2B |
Asthma and/or diabetes (preclinical) |
| Naxifylline |
A1 |
Heart failure (renal function) (discontinued) |
| FK-453 |
A1 |
Acute renal failure (preclinical) |
| Rolofylline |
A1 |
Heart failure (renal function) (discontinued) |
| Toponafylline |
A1 |
Heart failure (renal function) (IIb) |
| Vipadenant |
A2A |
Parkinson’s disease (II) |
